Paving the Way to Better Choices for Veterans With Lung Cancer: A Shared Decision-Making Approach to Treatment

Approximately 35,000 new cases of cancer occur in military veterans each year; cancer is the second leading cause of death among military veterans. According to the late Rear Admiral Philip J. Coady, USN, former Chairman of the Board of Directors of the Lung Cancer Alliance, “lung cancer is an urgent priority among veterans. 

This activity will provide education for clinicians on the incidence and prevalence of lung cancer in military veterans as well as the demographic/risk factors associated with this patient population to make appropriate clinical and management decisions with the patient. Because clinicians who work in VA facilities may not realize the importance of patient engagement and SDM with veterans and their caregivers, education will also be provided to assist clinicians in engaging military veterans in treatment decisions using SDM approaches and prioritizing the timeliness of care, coordination of care, screening, and access to palliative care for military veterans. ENROLL IN THIS ACIVITY

 

Making Progress for Improving Patient Lives: Clinical Advances in the First-Line Treatment of Advanced Squamous Non—Small Cell Lung Cancer

The goal of this activity is to close educational gaps by providing clinicians with the latest evidence-based data about current and emerging agents for the first-line treatment of advanced or metastatic squamous non-small cell lung cancer (NSCLC).

Clinicians need to remain apprised of emerging data offering additional treatment options for NSCLC, specifically for the first-line treatment of advanced or metastatic squamous NSCLC where few advances have been made over the past two decades and few options exist. This activity will address educational gaps related to the first-line treatment of advanced or metastatic squamous NSCLC and, as a result, help participants to make more informed decisions for their patients.  ENROLL IN THIS ACTIVITY

 

The Role of CDK 4/6 Inhibitors in the Management of Breast Cancer

This Virtual Grand Rounds initiative is designed to close these knowledge gaps and provide clinicians with up-to-date information about approved and emerging therapies so that they can make informed choices regarding the management of breast cancer.

Topics covered in this activity include the development of endocrine resistance in breast cancer; the significance of CDK inhibition; and the relevant clinical trial data about the efficacy and safety of CDK 4/6 inhibitors, such as abemaciclib, palbociclib, and ribociclib. This activity is intended for oncologists, pathologists, surgeons, nurses, and other healthcare professionals involved in the care and treatment of patients with HR+ breast cancer. ENROLL IN THIS ACIVITY

 

Failure Is Not an Option: Selecting Optimal Stem Cell Mobilization Strategies for Multiple Myeloma and Non-Hodgkin Lymphoma

There are many opportunities for healthcare professionals to improve the probability of successful mobilization in their patients with MM or NHL who are eligible for aHSCT. This activity will address available mobilization regimens for stem cell collection, identifying patients at risk for poor mobilization, and guidance for optimal regimen selection for each of their patients based on patient characteristics and cost of treatment. 

This activity is intended for medical oncologists, oncology nurses, transplant specialists, and other healthcare providers who treat or manage patients under consideration for stem cell mobilization and transplantation.  ENROLL IN THIS ACIVITY

 

Conquering Therapeutic Challenges in Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex: The Power of mTOR Inhibition

The goal of this activity is to close knowledge gaps on how to effectively treat and manage subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) and to provide clinicians with the necessary information to confidently use current and emerging agents to reduce symptoms while minimizing adverse effects. 

TSC is an autosomal dominant genetic disorder characterized by the systemic growth of benign, noninvasive legions, or hamartomas. Common sites of lesion growth include the brain, skin, kidney, heart, lung, and liver. TSC is frequently diagnosed before patients are 15 months old. The central nervous system is the most commonly affected system, affecting 85% to 90% of children and adolescents.  ENROLL IN THIS ACTIVITY

 

Transforming the Quality of Care for Patients With Immune Thrombocytopenia: Therapeutic and Management Approaches Making a Difference

Immune thrombocytopenia (ITP), once known as idiopathic thrombocytopenic purpura, is an autoimmune disorder that can occur acutely or chronically, and ranges in severity from mild to life-threatening. 

New treatments for both adults and children with ITP are continuously becoming available, challenging clinicians to optimally balance efficacy and safety when developing individualized treatment plans. This Virtual Grand Rounds initiative aims to close educational gaps and provide clinicians with up-to-date knowledge on current and emerging treatment strategies to make informed clinical choices to confidently treat and manage ITP.  ENROLL IN THIS ACTIVITY

 

Integrating the Latest Advances Into Clinical Practice: Data and Expert Insights From the 2016 Meeting on Genitourinary Cancers in San Francisco - Bladder Cancer

The goal of this activity is to provide clinicians with the latest clinical advances and emerging research in bladder cancer, as well as strategies to optimally integrate evolving evidence into clinical practice to improve the quality of care delivery.

In 2015, there were an estimated 138,710 new cases of urinary system cancers in the United States, with an estimated 30,970 deaths. Having access to the most recent clinical advances in GU malignancies is crucial to making informed and timely treatment decisions. This activity will highlight the most exciting and compelling data in bladder cancer, and provide insights on how these clinical advances may be practice changing.  ENROLL IN THIS ACTIVITY

 

Novel Oral Anticoagulants: Transforming Stroke Prevention in Nonvalvular Atrial Fibrillation

The goal of this activity is to provide clinicians with practical information on how best to Identify patients with nonvalvular atrial fibrillation who are most likely to benefit from timely initiation of novel oral anticoagulant therapy, to present an overview on the risks and benefits of current and emerging novel oral anticoagulants for patients with nonvalvular atrial fibrillation at risk for stroke, and to indicate how emerging novel oral anticoagulants and reversal therapies may affect the treatment landscape for nonvalvular atrial fibrillation.

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated with significant morbidity and mortality. If untreated, patients with AF have a 5-fold or higher risk for stroke than the general population.
ENROLL IN THIS ACTIVITY

 

Clinical Debates and Consensus Recommendations on the Use of Antiangiogenic Agents in Lung Cancer: A Focus on the Elderly Patient

This interactive lecture activity is designed to afford medical oncologists, thoracic oncologists, surgical oncologists, radiation oncologists, and other healthcare providers who treat or manage non–small cell lung cancer (NSCLC) the opportunity to engage in interdisciplinary dialogue with their peers and interact with experts from outside their institutions.

Discussions will focus on the angiogenesis pathway in NSCLC, the implementation of vascular endothelial growth factor (VEGF) inhibitors in older patients with NSCLC and its controversies, clinical results with use of VEGF inhibitors in older patients, and factors causing unintended treatment bias.  ENROLL IN THIS ACTIVITY

 

Defining Personalized Treatment Approaches in NSCLC: The Significance of EGFR Mutations

Non–small cell lung cancer is the most common form of lung cancer, accounting for more than 80% of newly diagnosed cases, with most patients having advanced stage disease. In adenocarcinomas, epidermal growth factor receptor (EGFR) gene mutations are prevalent in 10% of Western patients and in up to 50% of Asian patients.

Mutation analysis of the EGFR gene is an essential part of the diagnostic algorithm in patients with metastatic or recurrent NSCLC. EGFR mutation testing is recommended in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for metastatic NSCLC so that patients with this genetic abnormality can receive appropriate and effective targeted treatment.  ENROLL IN THIS ACTIVITY

 

Recent Courses

Title Credit Type Release and expiration date
Paving the Way to Better Choices for Veterans With Lung Cancer: A Shared Decision-Making Approach to Treatment
  • 1.00 ANCC credit
  • 1.00 Attendance credit
  • 1.00 AMA PRA Category 1 Credit™ credit
Enduring 09/20/2016 to 11/06/2017
The 2016 Advanced Clinical Educator Program in Multiple Myeloma: A CE-Certified Serial Learning Approach to Bridging Communication and Educational...
  • 1.00 ANCC credit
  • 1.00 Attendance credit
Enduring 09/08/2016 to 09/07/2017
Making Progress for Improving Patient Lives: Clinical Advances in the First-Line Treatment of Advanced Squamous Non—Small Cell Lung Cancer
  • 1.00 ANCC credit
  • 1.00 Attendance credit
  • 1.00 AMA PRA Category 1 Credit™ credit
Enduring 08/23/2016 to 12/20/2017
How checkpoint inhibitors are changing the treatment paradigm in solid tumors: what advanced practitioners in oncology should know
  • 1.10 ANCC credits
  • 1.10 Attendance credits
Enduring 07/12/2016 to 07/11/2017
Managing Metastatic NSCLC: Strategies for Treatment Selection
  • 1.00 ACPE credit
  • 1.00 ANCC credit
  • 1.00 AMA PRA Category 1 Credit™ credit
Enduring 07/12/2016 to 12/27/2017
The Role of CDK 4/6 Inhibitors in the Management of Breast Cancer
  • 0.75 Attendance credits
  • 0.75 AMA PRA Category 1 Credit™ credits
Enduring 07/01/2016 to 06/30/2017

Pages

Subscribe and receive timely updates

Returning AXIS Users

If you are an active AXISMedEd.com member, this site has been updated with enhanced functionality and security. You will need to create a new user profile and password. We apologize for any inconvenience this may cause. We truly appreciate you using AXISMedEd.com to meet your educational needs.

View the Courses You Have Completed

    Please login or create an account to view your activities.